AGRX - Agile Therapeutics: Why You Should Buy Now Before Upcoming Catalysts
It has been a rough couple years for Agile Therapeutics (AGRX), and the share price has taken the brunt of it. The company has been struggling for years to get their once-weekly contraceptive patch, Twirla, approved by the FDA. Twirla has received two CRLs from FDA, with the most recent occurring back in December of 2017. However, the company has complied with every FDA request and is quickly approaching another attempt at approval. Recently, the company announced that it received final meeting minutes from its December meeting with the FDA's Division of Bone, Reproductive, and